The manufacturers said the vaccine was undergoing larger, more comprehensive phase 3 trials to confirm the results.
Shortly after this, another USA pharmaceutical giant Pfizer said that its own vaccine jointly developed with BioNTech will have a 95 percent efficacy in preventing COVID-19 after its final analysis.
During the press conference, Spahn also announced the planned purchase of 5 million vaccine doses from the German pharmaceutical company IDT Biologika which expects its COVID-19 vaccine to be approved by the end of 2021.
A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said Thursday as it released its phase 2 trial results.
Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency United States authorization within days, it said on Wednesday. Europe's STOXX 600 and the U.S S&P 500 futures both rose about 0.3% to hit highs for the day.
Pfizer said vaccine was well-tolerated and that side effects were mostly mild to moderate, and cleared up quickly. A significant proportion of volunteers, however, experienced more severe aches and pains after taking the second dose, including about 10% who had fatigue severe enough to interfere with daily activities while another 9% had severe body aches.
"Nothing is signed yet, but we're close to a deal with the EU Commission".
The T-cell response - another measure of how well the immune system responds - peaked two weeks after the first dose of the vaccine, regardless of age. Moderna says the vaccine only requires standard refrigerator temperature of 2 to 8 degrees Celsius for 30 days, and can be stored for up to 6 months at minus 20 degrees Celsius.
"These vaccines, at the point of being administered to the American public, will have more data than any other vaccine developed in history", said Adams. Most of these complaints were generally short-lived, Moderna said. The vaccine was developed on a platform that had been used for a number of other vaccines.
"We can be fairly confident now that the RNA (vaccine approach) is looking good.That's also good for the Imperial College vaccine, which is an RNA vaccine".
The German government has launched a special program for the development of a COVID-19 vaccine for 750 million euros (892.5 million USA dollars), funding the German companies BioNTech, CureVac and IDT Biologika. Brussels also said it was in talks with Moderna about securing doses. "It's looking like a really contender". Russian Federation licensed its Sputnik-V COVID-19 vaccine for domestic use in August before it released data from large-scale trials.
